Genetherapy

Story Summary: 8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline, /PRNewswire-USNewswire/ — The Michael J. Fox Foundation for Parkinsons Research today announced more than in awards for 13 new projects to speed the discovery of biomarkers of PD. The development of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials. The lack of clear and reliable biomarkers of PD is one of the greatest hurdles to developing and testing new treatments that slow, stop or even prevent the disease a key unmet need for Parkinsons patients. The development of drug biomarkers is also critical to provide researchers with a tool for conclusively assessing whether a given drug is reaching brain areas of interest and/or achieving its desired effect. The following is a complete list of funded projects, which are made possible through the generous support of The Brin Wojcicki Foundation. T-Cell Receptor Changes as a Biomarker of Parkinsons DiseaseChuanhai Cao, PhD, , College of MedicineAnalysis of the Enteric Nervous System Using Routine Colonoscopy Biopsies: a Biomarker of Neurodegeneration in Parkinsons Disease?, MD, PhD, Department of Neurology, Inserm U913, , QE3 Trial Ancillary Biomarkers Study, MD, DPhil, Development of an mGluR5 Imaging Marker for Parkinsons Disease, MD, Institute for Neurodegenerative DisordersAssessing Heart Rate Variability in the Parkinsons Associated Risk Study Cohort, MD, The Parkinsons InstituteValidating the Electrocardiogram as a Tool to Identify Pre-Motor Parkinsons Disease, MD, The Parkinsons InstituteValidation of Neuroimaging Biomarkers for Nigrostriatal Neurons, MD, in The Role of Striatal Serotonergic Terminals in L-Dopa Induced-Dyskinesia in PD Patients, MD, PhD, FRCP, Imperial College Raising Antibodies to Alpha-Synuclein, MD, University of Biomarkers of Pioglitazone Effects in PD, MD, PhD, Beth Israel Deaconess Medical Center ()High Resolution Diffusion Tensor MRI Imaging as a Biomarker of Parkinsons Disease Diagnosis and Disease Progression, MD, High Resolution Diffusion Tensor Imaging in Parkinsons Disease and Parkinsons Plus Syndromes, PhD, Development of alpha6-selective Neuronal Nicotinic Receptor Imaging Agent as a Parkinsons Disease Biomarker, PhD, Targacept, Inc. The Michael J. Fox Foundation has been a leader in the development of PD biomarkers for several years, with investments of nearly to date. The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinsons disease through an aggressively funded research agenda….Read the Full Story

Related posts:

1. Michael J. Fox Foundation Awards (Dollor) 2.1 Million for High-Risk/High-Reward Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2009
2. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
3. Michael J. Fox Foundation Announces Support for LRRK2 Cohort Studies in Ashkenazi Jews and North-African Arab-Berbers